

ASX / Media Release

30 September 2009

---

## RHT: Resonance Health announces FerriScan<sup>®</sup> Rapide

Resonance Health Limited (ASX: RHT) is pleased to announce the launch of FerriScan<sup>®</sup> Rapide providing a significant benefit to patients and to radiology departments using the FerriScan<sup>®</sup> test.

The launch of FerriScan<sup>®</sup> Rapide delivers a 60% reduction in MRI scan time for patients without impacting the accuracy and precision our customers have come to expect. With the high cost of MRI, this announcement delivers a significant cost savings to MRI departments and patients. A 60% reduction in scan time (to approximately 10 minutes) will also make the FerriScan<sup>®</sup> test more accessible to paediatric patients who previously may have required sedation.

The Whittington Hospital in London has become the first medical site in the world to provide FerriScan<sup>®</sup> Rapide.

“As a centre of excellence in Thalassaemia and Sickle Cell Disease care, we are delighted to be leading the way in providing the latest technology to improve our patients’ health outcomes. FerriScan<sup>®</sup> Rapide replaces the need for liver biopsy in many cases and provides a valuable clinical tool for consultants to manage iron levels in their patients more effectively. By detecting iron overload, it can be better treated and managed.” Said Recep Suleyman, Imaging Services Manager at the Whittington Hospital.

The launch at the Whittington Hospital was attended by senior representatives from the Sickle Cell Society, the Thalassaemia Society, the Haemochromatosis Society, the CEO of the Whittington Hospital, consultants and patient representatives. The United Kingdom represents a significant market for FerriScan<sup>®</sup> with a large population of patients with iron overload and a springboard to the EU market.

This new FerriScan<sup>®</sup> Rapide test represents a significant step forward in our global rollout of FerriScan<sup>®</sup> making the test more affordable for patients with iron overload disorders.

By Order of the Board  
Resonance Health Limited

For further information please contact:

### Resonance Health

Liza Dunne  
Managing Director  
T: +61 8 9286 5300  
E: [lizad@resonancehealth.com](mailto:lizad@resonancehealth.com)

Stewart Washer  
Chairman  
T: +61 418 288 212  
E: [stewartw@resonancehealth.com](mailto:stewartw@resonancehealth.com)

---

Resonance Health Ltd (ASX: RHT) ([www.resonancehealth.com](http://www.resonancehealth.com)) is a medical device company providing core laboratory services utilising advanced medical technology for the analysis of medical images. Its patented technology FerriScan<sup>®</sup>, provides a safe and accurate alternative for measuring liver iron concentration, a significant issue for patients with iron overload. Initial commercialisation of FerriScan<sup>®</sup> has focused on pharmaceutical companies developing drug therapies to treat iron overload, and is now being extended to the broader international clinical community.